Skip to main content
. 2007 Dec 21;111(5):2563–2572. doi: 10.1182/blood-2007-10-116186

Table 1.

Chemotherapy regimen of study SWOG-9400

Agent Dose and route Days Notes
Induction part 1
    Daunorubicin 60 mg/m2 IV 1, 2, 3
    Vincristine 1.4 mg/m2 PO 1, 8, 15, 22 Maximum 2 mg per administration
    Prednisone 60 mg/m2 per day IV 1-42 Full dose to day 28, taper to day 42
    PEG-L-asparaginase 2000 units/m2 IM 15 Until protocol amendment of September 1, 1999
    L-Asparaginase 10 000 units/d IV or IM 15-24 After protocol amendment of September 1, 1999
Induction part 2 (patients with persistent leukemia on day 21)
    Daunorubicin 60 mg/m2 IV 22, 23
    Vincristine 1.4 mg/m2 PO 29, 36 Maximum 2 mg per administration
    Prednisone 60 mg/m2 per day IV Through day 42
    PEG-L-asparaginase 2000 units/m2 IM Day 38 Until protocol amendment of September 1, 1999, only
Consolidation
    Cyclophosphamide 650 mg/m2 IV 1, 15, 29
    Ara-C 75 mg/m2 per day IV push 2-5, 9-12, 16-19, 23-26
    6-Mercaptopurine 60 mg/m2 PO 1-28
    Methotrexate 10 mg/m2 IT or intraventricular 2, 9, 16, 23
Maintenance course 1
    6-Mercaptopurine 60 mg/m2 per day PO 1-63
    Methotrexate 20 mg/m2 per week PO 1-63
Maintenance course 2
    Vincristine 1.5 mg/m2 IV 1, 8, 15, 22 Maximum 2 mg per administration
    Adriamycin 25 mg/m2 IV 1, 8, 15, 22
    Dexamethasone 10 mg/m2 PO 1-28
Maintenance course 3
    Cyclophosphamide 650 mg/m2 IV 1
    Thioguanine 60 mg/m2 PO 1-14
    Ara-C 75 mg/m2 IV push 3-6, 10-13
Maintenance course 4
    6-Mercaptopurine 60 mg/m2 per day PO Daily for 2 y
    Methotrexate 20 mg/m2 per week PO Weekly for 2 y

IV indicates intravenously; PO, orally; IM, intramuscularly; and IT, intrathecally.